Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on depressive disorders and related symptom clusters. - Major depressive disorder: reduces depressive mood, anhedonia and associated functional impairment. - Depression with insomnia: improves sleep quality and reduces nighttime awakenings. - Depression with anxiety: alleviates anxiety symptoms and promotes overall emotional stability.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Hepatic injury or jaundice - Suicidal ideation or worsening depression - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hypersensitivity reactions

Before initiating Mirzaten, clinicians should consider several safety measures. - Monitor weight: patients often experience increased appetite and weight gain. - Assess sedation: drowsiness may affect driving or operating machinery. - Evaluate hepatic function: use cautiously in liver impairment. - Review psychiatric history: risk of worsening depression or emergent suicidal thoughts. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Central nervous system depressants (e.g., alcohol, benzodiazepines): additive sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): monitor for serotonin syndrome.